StocksMedium•6 October 2026•
1 min read
Genmab Epkinly Reduces Disease Progression Risk by 51% in DLBCL Trial
Key Facts
1Genmab's Epkinly showed a 51% reduction in the risk of disease progression or death in frontline DLBCL trials.
2Epkinly's efficacy notably exceeded Roche's Polivy in similar treatment settings.
Genmab's Epkinly showed a 51% reduction in the risk of disease progression or death in frontline trials for diffuse large B-cell lymphoma (DLBCL). Seeking Alpha reported that the Phase 3 trial results position the treatment as a potential market leader in its category.
The efficacy of Epkinly notably exceeded that of Roche's competitor drug, Polivy, in similar treatment settings. Regarding related equity performance, RHHVF closed at $427.89 on October 5, 2026, after trading between a session high of $430 and a low of $413.